An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals
作者:
M Nelson,
S Portsmouth,
J Stebbing,
M Atkins,
A Barr,
G Matthews,
D Pillay,
M Fisher,
M Bower,
B Gazzard,
期刊:
AIDS
(OVID Available online 2003)
卷期:
Volume 17,
issue 1
页码: 7-10
ISSN:0269-9370
年代: 2003
出版商: OVID
关键词: lamivudine;tenofovir;hepatitis B;HIV-1;antiretroviral therapy;resistance mutation
数据来源: OVID
摘要:
Background:Tenofovir is a novel nucleotide analogue recommended for use in HIV-1 infected treatment-experienced patients. Recent data suggest an effect on Hepatitis B virus (HBV) replication. We therefore investigated the use of tenofovir in HIV-1 and HBV co-infected individuals.Methods:Twenty HIV-1/HBV co-infected patients with a median of 108 weeks lamivudine experience (range, 0–270 weeks) received tenofovir 245 mg daily in addition to or as part of their combination antiretroviral therapy. Their immunologic parameters and HIV-1 RNA and HBV DNA viral loads were followed over a period of 52 weeks. In addition, their HBV DNA polymerase was sequenced at baseline to measure the frequency of YMDD mutations that are associated with lamivudine resistance.Findings:A significant decrease in HBV DNA viral load (4 × log10) and alanine aminotransferase levels was observed. There were no significant overall differences between the lamivudine-experienced (n = 15) and -naive (n = 5) individuals and tenofovir was well tolerated. Five patients (25%) underwent HBe antigen seroconversion during the study period. Out of the 15 lamivudine-experienced individuals, 10 had YMDD mutations and one had YIDD mutations in HBV DNA.Interpretation:These results indicate that 52 weeks of tenofovir in addition to antiretroviral therapy is active against HBV, and it appears to overcome lamivudine resistance.
点击下载:
PDF
(83KB)
返 回